From: Clinical features and death risk factors in COVID-19 patients with cancer: a retrospective study
Clinical features | All patients (n = 103) | Survivor (n = 91) | Non-survivor (n = 12) | P-value |
---|---|---|---|---|
Age | 66.0 (24.0–90.0) | 66 (24.0–90.0) | 66 (56.0–81.0) | 0.487 |
Gender | 0.061 | |||
Female | 47 (45.6%) | 45 (44.6%) | 2 (16.7%) | |
Male | 56 (54.4%) | 56 (55.4%) | 10 (83.3%) | |
Smoking | 20 (19.4%) | 16 (17.6%) | 4 (33.3%) | 0.242 |
Comorbidities | ||||
Diabetes | 14 (13.6%) | 13 (14.3%) | 1 (8.3%) | 1.000 |
Hypertension | 37 (35.9%) | 36 (39.6%) | 1 (8.3%) | 0.052 |
Heart disease | 11 (10.7%) | 9 (9.9%) | 2 (16.7%) | 0.613 |
Symptoms | ||||
Fever | 73 (70.9%) | 63 (69.2%) | 10 (83.3%) | 0.501 |
Cough | 70 (68.0%) | 63 (69.2%) | 7 (58.3%) | 0.183 |
Dyspnea | 24 (23.3%) | 16(17.6%) | 8 (66.7%) | 0.003 |
Vomiting | 5 (4.9%) | 4 (4.4%) | 1 (8.3%) | 0.34 |
Diarrhoea | 7 (6.8%) | 6 (6.7%) | 1 (8.3%) | 0.235 |
Laboratory findings | ||||
WBC (× 109/L) | 5.29 (1.90–25.10); n = 100 | 5.09 (1.90–25.10); n = 88 | 7.36 (3.50–18.80); n = 12 | < 0.001 |
Neutrophil (× 109/L) | 3.49 (0.67–22.40); n = 100 | 3.25 (0.67–22.40); n = 88 | 6.85 (1.50–17.36); n = 12 | < 0.001 |
Lymphocyte (× 109/L) | 1.06 (0.22–2.89); n = 100 | 1.15 (0.33–2.89); n = 88 | 0.64 (0.22–2.40); n = 12 | 0.012 |
NLR | 2.93 (0.64–32.23); n = 100 | 2.64 (0.64–24.76); n = 88 | 11.7 (2.88–32.32); n = 12 | < 0.001 |
CRP (mg/L) | 2.52 (0.14–280.32); n = 90 | 1.79 (0.14–177.80); n = 81 | 80.00 (4.80–280.32); n = 9 | < 0.001 |
ALT (U/L) | 19.17 (4.50–131.20); n = 97 | 19.17 (4.50–131.20); n = 85 | 16.50 (6.00–68.30); n = 12 | 0.634 |
AST (U/L) | 21.70 (10.00–147.20); n = 84 | 21.20 (10.00–147.20); n = 72 | 31.35 (12.00–92.6); n = 12 | 0.164 |